This research appears in the first issue for November 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
Lara Shekerdemian, M.D., of the Pediatric Intensive Care Unit at the Royal Children's Hospital in Melbourne, Australia, and five associates gave a single dose of sildenafil to 15 infants undergoing withdrawal from inhaled nitric oxide therapy. None experienced rebound pulmonary hypertension, a common therapeutic complication.
Fourteen children in the study cohort received a placebo. Ten of the 14 had an acute elevation of pulmonary artery pressure by 20 percent or more during the latter part of the weaning process.
Inhaled nitric oxide was first introduced in the early 1990s as a therapeutic agent to widen pulmonary blood vessels in ventilated lung regions by relaxing pulmonary vascular smooth muscle.
Although there have been no definitive studies of clinical benefit to date, the investigators believe that inhaled nitric oxide therapy warrants use as an adjunctive treatment in some of the sickest patients in the ICU. They call it "unrivaled" in its efficacy as a selective pulmonary vasodilator.
"An important complication that is associated with the use of inhaled nitric oxide is the development of rebound pulmonary hypertension on its withdrawal," said Dr. Shekerdemian.
All infants who failed to respond were given sildenafil during a subsequent weaning attempt more than 24 hours later and were weaned successfully from nitric oxide treatment.
The total duration of ventilation for patients given sildenafil was slightly over 28 hours, as compared with 98 hours for those taking a placebo.
"The total ICU stay after the study was completed was 47.8 hours for the sildenafil group and 189 hours for the placebo group," added Dr. Shekerdemian.
"This study is unique in a number of ways," she continued. "It is the first study to investigate the pharmacologic prophylaxis of rebound pulmonary hypertension during the primary attempt to wean from inhaled nitric oxide. This is also the first prospective trial of sildenafil in the prevention of rebound pulmonary hypertension. Moreover, this study is the first that defines the extent of the problem of rebound pulmonary hypertension in infants and children weaning from inhaled nitric oxide in the pediatric ICU."
Suzy Martin | EurekAlert!
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
21.03.2018 | Physics and Astronomy
21.03.2018 | Materials Sciences
21.03.2018 | Life Sciences